Hepatoblastoma
Everything in the library about hepatoblastoma — built automatically from the recorded discussions that name it
Educational content from recorded physician discussions — not medical advice. Always talk to your child's care team about your child's situation.
Content of this collection
Surgical Management
4 items
Hepatoblastoma: Update Course 2014
Watch →
Dr. Matthew Clifton gives a presentation on hepatoblastoma including discussion of pre-treatment extent of disease (pretext) and post-treatment extent of disease staging for hepatoblastoma, management and surgical resection based on stages,
video24:43 · Nov 2018
Hepatoblastoma: Update Course 2014
Watch →
During the 2nd Annual Stay Current in Pediatric Surgery Update Course in 2014,Dr. Matthew Clifton presents on hepatoblastoma.Topics discussed includepre-treatment extent of disease (pretext) and post-treatment extent of disease staging for
video · Jan 2019
Indocyanine green is a sensitive adjunct in the identification and surgical management of local and metastatic hepatoblastoma
Watch →
Charissa M Lake, Alexander J Bondoc, Roshni Dasgupta, Todd M Jenkins, Alexander J Towbin, Ethan A Smith, Maria H Alonso, James I Geller, Gregory M TiaoBackground: Hepatoblastoma is the most common primary pediatric liver malignancy. Indocya
video1:04 · Jan 2026
Characteristics of Transfusion and Association With Oncologic Outcomes in Hepatoblastoma Resection
Watch →
Stephanie F Polites, Jennifer H Aldrink, Timothy B Lautz, Robert A Vierkant, Mecklin V Ragan, Audra Reiter, Stephanie Y Chen, Eugene S Kim, Hannah N Rinehardt, Marcus M Malek, Andrew M Fleming, Andrew J Murphy, Jonathan P Roach, Sridharan R
video1:10 · Apr 2026
Complications
1 item
Early Postoperative Fever in Pediatric Oncology Patients Undergoing Solid Tumor Resection
Watch →
John Lundstedt, Emily Vore, Joseph Brungardt, Meera Kotagal, Todd Jenkins, Chloe Boehmer, Roshni DasguptaBackgroundPostoperative fever is common following cancer resection and often prompts extensive, costly workups. The purpose of this stu
video0:51 · Dec 2025
Evidence & Research
3 items
BOB Ped Surg 2023 - Andrew Fleming, AAP - Presentation
Watch →
Watch Andrew Fleming, MD, present his presentation on "Aggressive Pursuit of No Evidence of Disease Status in Hepatoblastoma Improves Survival."
video · Feb 2023
Aggressive Pursuit of No Evidence of Disease Status in Hepatoblastoma Improves Survival
Watch →
Another article you should know abou by Cecilia Gigena
“Aggressive Pursuit of No Evidence of Disease Status in Hepatoblastoma Improves Survival: An observational study” Fleming A et.al.
Authors: Andrew M. Fleming, Andrew J. Murphy, Su
video · Jun 2023
Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience
Watch →
Katherine M Somers, Rachel Bernstein Tabbouche, Alexander Bondoc, Alexander J Towbin, Sarangarajan Ranganathan, Greg Tiao, James I GellerBackground: Hepatoblastoma (HB) is the most common liver malignancy in children. There is no standard o
video1:10 · Jan 2026
Case-Based Learning
1 item
Clinical & Research Update: Pediatric Liver Tumors - A Case-Based Discussion with Drs. Katherine Somers & Alex Bondoc
Watch →
This live event offered a focused, case-based conversation exploring current approaches to pediatric liver tumors across four critical domains:• Liver transplantation — indications, timing, and outcomes• Relapse management — surveillance an
video69:23 · Apr 2026
In-Depth Reviews
3 items
Hepatoblastoma
Listen →
This is an interactive discussion between Todd Ponsky, MD and Max Langham, MD on the management of hepatoblastomas. Dr. Max Langham is a Professor of Surgery and Pediatrics and the Vice Chairman of the Department of Surgery at the Universi
podcast54:16 · Dec 2020
Hepatoblastoma with Dr. Greg Tiao
Listen →
Hepatoblastoma is the most common malignant liver tumor in the pediatric population but treatment strategies have changed dramatically over the past couple of decades so today we will review the basics of hepatoblastoma with Dr. Greg Tiao,
podcast10:12 · Feb 2022
Hepatoblastoma with Dr. Greg Tiao
Watch →
Hepatoblastoma is the most common malignant liver tumor in the pediatric population. But treatment strategies have changed dramatically over the past 25 years. That’s why today, were going to review the basics-with an expert.
00:27:38-0027:
video · Mar 2022
Long-Term Care
1 item
Quality of Life Outcomes for Patients Who Underwent Conventional Resection and Liver Transplantation for Locally Advanced Hepatoblastoma
Watch →
Zishaan Farooqui, Michael Johnston, Emily Schepers, Nathalie Brewer, Stephen Hartman, Todd Jenkins, Alexander Bondoc, Ahna Pai, James Geller, Gregory M TiaoAbstract:Hepatoblastoma is the most common malignant liver tumor of childhood, with
video1:05 · Jan 2026
Summaries and takeaways+ Show
The doctors in this collection+ Show
All expert statements+ Show
Every expert statement below comes from the recorded discussions, with its speaker and moment.
Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience
There is no established standard salvage therapy regimen for relapsed hepatoblastoma
guidelineSophia Schermerhorn0:12 ↗
The Cincinnati Children's retrospective review of 30 patients represents one of the largest published cohorts evaluating patients with refractory or recurrent hepatoblastoma
epidemiologicalSophia Schermerhorn0:17 ↗
The overall survival for the cohort was about 50%
clinicalSophia Schermerhorn0:25 ↗
Children who received cisplatin as part of their salvage therapy had survival of about 80% compared to 25% for those who did not receive cisplatin
clinicalSophia Schermerhorn0:28 ↗
The improved survival outcomes with cisplatin may be due to persistent platinum sensitivity or better tumor biology rather than proving causality
opinionSophia Schermerhorn0:36 ↗
Most patients underwent additional surgery as part of their salvage therapy, either liver resection, liver transplant, or pulmonary metastasectomy
clinicalSophia Schermerhorn0:49 ↗
Salvage therapy for relapsed hepatoblastoma is multimodal
clinicalSophia Schermerhorn0:57 ↗
Cisplatin retreatment should be balanced with the risk of cumulative toxicity
opinionSophia Schermerhorn0:59 ↗
Indocyanine green is a sensitive adjunct in the identification and surgical management of local and metastatic hepatoblastoma
This is a single institution retrospective review of patients who received ICG prior to either pulmonary metastatectomy or liver resection for hepatoblastoma
clinicalSophia Schermerhorn0:12 ↗
ICG was highly sensitive for detecting hepatoblastoma, about 90%
clinicalSophia Schermerhorn0:22 ↗
In a meaningful number of cases, ICG was able to detect tumor deposits that were not visible, palpable, or detectable on preoperative imaging
clinicalSophia Schermerhorn0:27 ↗
Specificity was lower than sensitivity with false positives
clinicalSophia Schermerhorn0:39 ↗
False positives often represented vascular changes or inflammation
clinicalSophia Schermerhorn0:43 ↗
There were no adverse outcomes associated with any of the additional resections guided by ICG
clinicalSophia Schermerhorn0:46 ↗
ICG was effective in both open and minimally invasive surgery
clinicalSophia Schermerhorn0:50 ↗
ICG was effective in both relapse and primary disease
clinicalSophia Schermerhorn0:50 ↗
Quality of Life Outcomes for Patients Who Underwent Conventional Resection and Liver Transplantation for Locally Advanced Hepatoblastoma
This is a single institution cross-sectional study using validated pediatric quality of life surveys to evaluate long-term survivors of hepatoblastoma.
clinicalSophia Schermerhorn0:24 ↗
Survival for hepatoblastoma continues to improve.
epidemiologicalSophia Schermerhorn0:18 ↗
Long-term quality of life is becoming a more important outcome as hepatoblastoma survival improves.
opinionSophia Schermerhorn0:18 ↗
Overall quality of life outcomes were similar between liver transplant and resection groups for hepatoblastoma.
clinicalSophia Schermerhorn0:31 ↗
There was no significant difference in emotional, social, physical, or school functioning outcomes between transplant and resection groups.
clinicalSophia Schermerhorn0:31 ↗
Patients who underwent resection had lower overall procedure anxiety scores than transplant patients.
clinicalSophia Schermerhorn0:47 ↗
The finding of lower procedural anxiety in resection patients was mirrored in the parents' surveys.
clinicalSophia Schermerhorn0:53 ↗
Long-term quality of life outcomes appear comparable between patients who undergo resection and liver transplantation for hepatoblastoma.
clinicalSophia Schermerhorn0:55 ↗
Surgical strategy for hepatoblastoma can be focused on oncologic control given comparable quality of life outcomes.
opinionSophia Schermerhorn1:02 ↗
Characteristics of Transfusion and Association With Oncologic Outcomes in Hepatoblastoma Resection
It is not uncommon for a patient with hepatoblastoma to need a transfusion during resection
clinicalJill Knepprath0:00 ↗
The study was multi-institutional and published in Pediatric Blood and Cancer in 2025
epidemiologicalJill Knepprath0:13 ↗
The study examined how intraoperative transfusion may affect recurrence and survival in hepatoblastoma resection patients
epidemiologicalJill Knepprath0:19 ↗
Of those transfused, the majority received red blood cells
epidemiologicalJill Knepprath0:25 ↗
Only 11% of transfused patients received platelets
epidemiologicalJill Knepprath0:25 ↗
What's new+ Show